Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in Tennessee: - Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in Tennessee: - Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 3 Recruiting Industry
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years …
Sponsor: Pfizer
NCT ID: NCT06152575
Sites in Tennessee: - Ascension St. Thomas Hospital — Nashville, Tennessee
- Tennessee Oncology, PLLC - Investigational Drug Services — Nashville, Tennessee
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers — Nashville, Tennessee
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza DDU — Nashville, Tennessee
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology — Nashville, Tennessee
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…
Sponsor: Celgene
NCT ID: NCT05519085
Sites in Tennessee: - The West Clinic, PLLC dba West Cancer Center — Germantown, Tennessee
Phase 3 Recruiting Industry
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, inclu…
Sponsor: Kite, A Gilead Company
NCT ID: NCT06413498
Sites in Tennessee: - University of Tennessee Medical Center — Knoxville, Tennessee
- Baptist Cancer Center — Memphis, Tennessee
- Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research — Nashville, Tennessee
- Henry-Joyce Cancer Clinic — Nashville, Tennessee
Phase 3 Recruiting Industry
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…
Sponsor: AbbVie
NCT ID: NCT06158841
Sites in Tennessee: - University of Tennessee Health Science Center /ID# 261622 — Memphis, Tennessee
- Baptist Memorial Hospital /ID# 270910 — Memphis, Tennessee
- The West Clinic /ID# 262444 — Memphis, Tennessee
- Vanderbilt University Medical Center /ID# 261621 — Nashville, Tennessee
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Sponsor: Bristol-Myers Squibb
NCT ID: NCT05827016
Sites in Tennessee: - West Cancer Center — Germantown, Tennessee
- Tennessee Oncology — Nashville, Tennessee
Phase 3 Recruiting Industry
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, …
Sponsor: AstraZeneca
NCT ID: NCT07391657
Sites in Tennessee: - Research Site — Nashville, Tennessee
Phase 3 Recruiting Network
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as …
Sponsor: European Myeloma Network B.V.
NCT ID: NCT05243797
Sites in Tennessee: - Vanderbilt-Ingram Cancer Center (VICC) — Nashville, Tennessee
Phase 2, Phase 3 Recruiting Industry
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…
Sponsor: AbbVie
NCT ID: NCT07095452
Sites in Tennessee: - SCRI Oncology Partners /ID# 278353 — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in Tennessee: - Tennessee Oncology - Nashville / Sarah Cannon Research Institute — Nashville, Tennessee
Phase 2 Recruiting NIH
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06179888
Sites in Tennessee: - Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in Tennessee: - Tennessee Oncology — Nashville, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Academic/Other
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period o…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06232044
Sites in Tennessee: - Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Sponsor: AstraZeneca
NCT ID: NCT05850234
Sites in Tennessee: - Research Site — Nashville, Tennessee
- Research Site — Nashville, Tennessee
Phase 2 Recruiting Industry
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants w…
Sponsor: Sanofi
NCT ID: NCT06356571
Sites in Tennessee: - Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road- Site Number : 8400035 — Knoxville, Tennessee
- University of Tennessee Medical Center- Site Number : 8400006 — Knoxville, Tennessee
- Tennessee Oncology Nashville- Site Number : 8400012 — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in Tennessee: - TriStar Centennial Medical Center — Nashville, Tennessee
Phase 2 Recruiting Industry
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called r…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07266441
Sites in Tennessee: - SCRI Oncology Partners — Nashville, Tennessee
- Tennessee Oncology, PLLC — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT05972135
Sites in Tennessee: - TriStar Bone Marrow Transplant — Nashville, Tennessee
- Vanderbilt- Ingram Cancer Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and ne…
Sponsor: Karyopharm Therapeutics Inc
NCT ID: NCT02343042
Sites in Tennessee: - Sarah Cannon- Tennessee Oncology Nashville — Nashville, Tennessee
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT04634552
Sites in Tennessee: - Tennessee Oncology — Nashville, Tennessee
Phase 2 Recruiting Network
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be a…
Sponsor: Multiple Myeloma Research Consortium
NCT ID: NCT06171685
Sites in Tennessee: - Tennessee Oncology — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumu…
Sponsor: Indapta Therapeutics, INC.
NCT ID: NCT06119685
Sites in Tennessee: - SCRI Oncology Partners — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
Sponsor: ModernaTX, Inc.
NCT ID: NCT07116616
Sites in Tennessee: - Sarah Cannon Research Institute — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of…
Sponsor: University of Alabama at Birmingham
NCT ID: NCT05231629
Sites in Tennessee: - Vanderbilt University — Nashville, Tennessee